Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Predictive Models for Carboplatin with or without Hyperthermia Treatment Response in Epithelial Ovarian Cancer: Comparison of 2D, 3D, and in-vivo Models

EF 2018-19

Résumé
Despite many advances in surgical techniques and chemotherapies, ovarian cancer (OC) remains a deadly disease with only half of patients surviving 5 years after diagnosis. To address this issue, research has shifted to develop a more personalized medicine approach, which dictates that each cancer patient be paired to her most appropriate treatment. Direct testing of treatments on biopsied tumor mass (or derivative) may enable to predict patient response. Our laboratory has been a leader in developing new model systems to evaluate drug response, including using microtumors in devices that allow treatment testing. Our recent unpublished data has shown that the sensitivity of our patient-derived samples to carboplatin, the most used chemotherapy in OC, does not perfectly correlate when tested in 2D and 3D models. This is concerning since the accuracy of a pre-clinical model is essential for predicting patient response. We believe that the precision of treatment testing is related to the tissue spatial composition, in which the closer a model is to the initial tumor sample, the better the prediction power it will have. To this end, we will categorize and compare the sensitivities of OC tumor samples to 2 different treatments across 2D, 3D and mouse models to determine the most accurate pre-clinical model. The 2 treatments to be tested are carboplatin and/or hyperthermic treatment (HT), which involves heating a solution above 37°C and has been shown to increase survival in OC patients. This study will enlighten researchers on determining the pre-clinical model with the highest translational potential for predicting patient outcomes in the new era of precision medicine.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406473
Name
Brodeur Melica Nourmoussavi
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Predictive Models for Carboplatin with or without Hyperthermia Treatment Response in Epithelial Ovarian Cancer: Comparison of 2D, 3D, and in-vivo Models
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Hyperthermic Treatment; Ovarian Cancer; Predictive Pre-Clinical Models
Abstract
Despite many advances in surgical techniques and chemotherapies, ovarian cancer (OC) remains a deadly disease with only half of patients surviving 5 years after diagnosis. To address this issue, research has shifted to develop a more personalized medicine approach, which dictates that each cancer patient be paired to her most appropriate treatment. Direct testing of treatments on biopsied tumor mass (or derivative) may enable to predict patient response. Our laboratory has been a leader in developing new model systems to evaluate drug response, including using microtumors in devices that allow treatment testing. Our recent unpublished data has shown that the sensitivity of our patient-derived samples to carboplatin, the most used chemotherapy in OC, does not perfectly correlate when tested in 2D and 3D models. This is concerning since the accuracy of a pre-clinical model is essential for predicting patient response. We believe that the precision of treatment testing is related to the tissue spatial composition, in which the closer a model is to the initial tumor sample, the better the prediction power it will have. To this end, we will categorize and compare the sensitivities of OC tumor samples to 2 different treatments across 2D, 3D and mouse models to determine the most accurate pre-clinical model. The 2 treatments to be tested are carboplatin and/or hyperthermic treatment (HT), which involves heating a solution above 37°C and has been shown to increase survival in OC patients. This study will enlighten researchers on determining the pre-clinical model with the highest translational potential for predicting patient outcomes in the new era of precision medicine.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Brodeur, Melica Nourmoussavi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~